Dr. Jeffrey DeClaire and the medical team at Michigan Knee Institute use the latest medical technology with a state-of-the-art medical facility to provide our patients with the best possible outcomes, for injured and damaged knees.

MYMOBILITY® CLINICAL STUDY

Dr. DeClaire is one of 30 orthopaedic practices in the US participating in the Zimmer Biomet mymobility® Clinical Study.

In collaboration with Apple, Zimmer Biomet is attempting to transform the patient journey for two of the most common surgeries that Americans undergo each year – knee and hip replacement. This collaboration has yielded mymobility®, an app that uses Apple Watch® and iPhone® to facilitate a new level of connection between patients and their surgeons, which may improve the often challenging journey that patients experience, while also delivering continuous data to surgeons so they can optimize care and improve outcomes.

The mymobility® patient experience keeps patients informed and educated on next steps through notifications, video tutorials, to-dos, and reminders throughout their journey with its intuitive and straightforward interface. For the first time, this study will combine patient-reported feedback with continuous biometric and behavioral data from the mymobility® with Apple Watch® solution, providing new information about the patient journey. Understanding their condition and care plan gives patients the ability to participate in optimizing their surgical outcome actively.

 
ARE YOU INTERESTED IN PARTICIPATING? CONTACT US TO FIND OUT IF YOU QUALIFY.

mymobility® is a registered trademark of Zimmer Biomet. Apple Watch and iPhone are registered trademarks of Apple, Inc.

omnibotics® Omnibot™

Over 100 cases have now been performed with OMNIlife science’s OMNIBotics® OMNIBot™ in its multi-center U.S. clinical study.

The study is assessing the combination of robotic-assisted bone cutting with active soft tissue management at five sites; more are slated to enter the study over several months. Results from the first four sites mirror the positive outcomes observed in the Australian pilot program underway since 1Q17.

OMNIBot™ is reportedly the only available system that supports predictive balance of ligaments through dynamic, real-time feedback across the entire range of motion that can deliver computer-calculated, robotic-assisted bone cutting.

Sources: OMNIlife science, Inc.; ORTHOWORLD Inc.

Research Papers